Penfluridol in the treatment of newly admitted schizophrenic patients in a brief therapy unit.
The authors compared penfluridol, a long-acting neuroleptic that can be administered orally once a week, with chlorpromazine in the treatment of 33 newly admitted schizophrenic patients in a brief therapy unit. Patients receiving either drug improved enough to be discharged in 3 weeks. Penfluridol-treated patients experienced less drowsiness than those treated with chlorpromazine, but the severity of extrapyramidal symptoms appeared to be greater with penfluridol.
D001480:Basal Ganglia Diseases / Q000139:chemically induced; D002746:Chlorpromazine / Q000627:therapeutic use; D003244:Consciousness Disorders / Q000139:chemically induced; D006801:Humans; D007902:Length of Stay; D010395:Penfluridol / Q000627:therapeutic use*; D010880:Piperidines / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy*
D010880:Piperidines; D010395:Penfluridol; D002746:Chlorpromazine